Deals Of The Week: United Therapeutics/Ascendis, Baxter/Onconova, Bionomics/Eclipse
The growing importance of emerging markets was a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
You may also be interested in...
The antibody drug conjugate showed a significant overall survival benefit in HER2-positive metastatic breast cancer in the EMILIA trial, the company announced.
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.